Cabaletta Bio, Inc.
About Cabaletta Bio, Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$167.9M
- Total assets
- $165.1M
- Market cap
- $529.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $172.2M
- Operating income
- -$172.2M
- Income tax
- $0
- Net income
- -$167.9M
- EPS (basic)
- $-2.10
- EPS (diluted)
- $-2.10
Balance sheet
- Total assets
- $165.1M
- Current assets
- $138.9M
- Total liabilities
- $53.0M
- Current liabilities
- $50.2M
- Shareholders’ equity
- $112.1M
Cash flow
- Operating cash flow
- -$131.1M
- Investing cash flow
- -$50.3M
- Financing cash flow
- $100.3M
- Net cash flow
- -$81.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $529.9M
- EPS (diluted)
- $-2.1
- Shares outstanding
- 165.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 25, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $167.9M.
- Trading 23% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cabaletta Bio, Inc..
Write a review
News about Cabaletta Bio, Inc.
News & sentiment via Polygon.io
